Published in final edited form as:

Angew Chem Int Ed Engl. 2014 June 23; 53(26): 6687–6691. doi:10.1002/anie.201403588.

Synthetic Disialyl Hexasaccharides Protect Neonatal Rats from Necrotizing Enterocolitis**

Hai Yu,

Department of Chemistry, University of California, Davis, One Shields Avenue, Davis, CA 95616 (USA)

Kam Lau,

Department of Chemistry, University of California, Davis, One Shields Avenue, Davis, CA 95616 (USA)

Vireak Thon,

Department of Chemistry, University of California, Davis, One Shields Avenue, Davis, CA 95616 (USA)

Chloe A. Autran,

Division of Neonatology and Division of Gastroenterology and Nutrition, Department of Pediatrics, University of California-San Diego, La Jolla, CA 92093 (USA)

Evelyn Jantscher-Krenn,

Division of Neonatology and Division of Gastroenterology and Nutrition, Department of Pediatrics, University of California-San Diego, La Jolla, CA 92093 (USA)

Mengyang Xue,

Department of Chemistry, University of California, Davis, One Shields Avenue, Davis, CA 95616 (USA), National Glycoengineering Research Center, College of Life Sciences, Shandong University, Jinan, Shandong 250100 (China)

Yanhong Li,

Department of Chemistry, University of California, Davis, One Shields Avenue, Davis, CA 95616 (USA)

Go Sugiarto,

Department of Chemistry, University of California, Davis, One Shields Avenue, Davis, CA 95616 (USA)

**The authors thank Prof. Peng George Wang at the Georgia State University for providing the plasmid expressing recombinant NmLgtA and Liwen Deng at the Mouse Phenotyping Core, University of California, San Diego for tissue preparation, sectioning and H&E staining. This work was supported by NIH grant R01HD065122 (to X.C.) and NIH grant R00DK078668 (to L.B.). X.C. is a Camille Dreyfus Teacher-Scholar and a UC-Davis Chancellor's Fellow. Bruker Avance-800 NMR spectrometer was funded by NSF grant DBIO-722538.

© 2013 Wiley-VCH Verlag GmbH & Co. KGaA

Correspondence to: Xi Chen, xiichen@ucdavis.edu.

K. Lau, Current address: Institute for Glycomics, Gold Coast Campus, Griffith University, Queensland 4222 (Australia)

Dr. V. Thon, Current address: Laboratory of Bacterial Polysaccharides, Food and Drug Administration, Bethesda, MD 20892 (USA)

Dr. J. Qu, Current address: Department of Chemistry, Georgia State University, Atlanta, GA 30303 (USA)

Dr. L. Ding, Current address: College of Life Science, Northwest University, Xi'an, Shaanxi 710069 (China)

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/anie.201xxxxx>.

Jingyao Qu,

Department of Chemistry, University of California, Davis, One Shields Avenue, Davis, CA 95616 (USA)

Shengmao Mu,

Department of Chemistry, University of California, Davis, One Shields Avenue, Davis, CA 95616 (USA)

Li Ding,

Department of Chemistry, University of California, Davis, One Shields Avenue, Davis, CA 95616 (USA)

Lars Bode, and

Division of Neonatology and Division of Gastroenterology and Nutrition, Department of Pediatrics, University of California-San Diego, La Jolla, CA 92093 (USA)

Xi Chen

Department of Chemistry, University of California, Davis, One Shields Avenue, Davis, CA 95616 (USA)

Xi Chen: xiichen@ucdavis.edu

Keywords

disialyl glycan; enzymatic synthesis; necrotizing enterocolitis; oligosaccharide; one-pot multienzyme

Human milk oligosaccharides (HMOS) are a mixture of more than 100 glycans which constitute the third major component of human milk.^[1] They have been found to contribute significantly to the gut health of breastfed infants. Strong evidences are available now to support the roles of HMOS on promoting the growth of beneficial gut bacteria; inhibiting the binding of pathogenic bacteria, human immunodeficiency virus (HIV), or protozoan parasites to gut epithelial cells; modulating immune responses; and influencing the functions of gut epithelium.^[2]

Most of the reported HMOS-related studies used HMOS mixtures and thus the key active components are not clear. Among a few individual HMOS with known functions, disialyllacto-*N*-tetraose (DSLNT, Figure 1), but not its non-sialylated or mono-sialylated analog, was previously identified as a specific HMOS component that is effective for preventing necrotizing enterocolitis (NEC) in a neonatal rat model.^[3] DSLNT contains two sialic acid residues: one is linked to the terminal galactose (Gal) residue via an α 2–3-sialyl linkage; the other is linked to the internal *N*-acetylglucosamine (GlcNAc) residue via an α 2–6-sialyl linkage (Figure 1). The hexasaccharide is presented at a level of 0.2–0.6 gram in a liter of human milk.^[4] However, it is not presented in porcine milk,^[5] and either is not presented^[6] or exists only in trace amount in bovine milk.^[4, 7] Due to the limited availability of human milk and the absence or the low abundance of DSLNT in bovine milk, it is impractical to obtain the compound in large scale for potential clinical therapeutic applications. Furthermore, despite the identification of the activity of an α 2–6-

sialyltransferase (e.g. in the livers of various animals and human as well as in human placenta, bovine mammary gland, human milk, and human mammary tumor although at a lower level) that catalyzes transfer of sialic acid α 2–6-linked to the internal GlcNAc residue in DSLNT,^[8] the gene for the enzyme has not been identified. Therefore, it is currently unfeasible to obtain the desired α 2–6-sialyltransferase in large amount to allow large-scale enzymatic synthesis of DSLNT. On the other hand, sialosides remain to be challenging targets for large scale chemical synthesis due to the intrinsic structural feature of sialic acids (e.g. steric hindered anomeric carbon with a connecting electron-withdrawing carboxyl group in the sialic acid which lowers the glycosylation reactivity and efficiency and the lack of a neighbouring participating group that disallows the precise control of the sialylation stereospecificity).^[9] Recent advances in the development of chemical methods for synthesizing sialosides overcame some of the challenges and significantly improved synthetic yields and stereoselectivity. Nevertheless, despite the synthesis of a more complex DSLNT-containing glycosyl ceramide (35 mg) reported by the Kiso group,^[10] chemical synthesis of DSLNT in a free oligosaccharide form has not been reported.

One strategy to overcome the challenges in obtaining DSLNT in a large amount for NEC studies and potential therapies is to identify compounds that have similar or better NEC-preventing effects than DSLNT and can be easily obtained synthetically. Here, we report that two novel synthetic disialyl hexasaccharides, including α 2–6-linked disialyllacto-*N*-neotetraose (DSLNT) obtained by sequential one-pot multienzyme (OPME) reactions and α 2–6-linked disialyllacto-*N*-tetraose (DS'LNT) obtained by one-pot sialylation of lacto-*N*-tetraose (LNT), have potent NEC-preventing effect. DSLNT can be produced in a large amount from simple starting materials for potential therapeutic applications.

In nature, the key enzymes that catalyze the glycosidic bond formation are glycosyltransferases (GlyT). GlyT-catalyzed transfer of monosaccharides other than sialic acids can be achieved most efficiently via a three-enzyme process: activation of a monosaccharide by a glyco kinase (GlyK) to form a sugar-1-phosphate (monosaccharide-1-P), which can be used by a nucleotidyltransferase (NucT) for the synthesis of a nucleoside diphosphate monosaccharide, the sugar nucleotide donor substrate of a suitable glycosyltransferase (GlyT) for the formation of a desired glycosidic bond in the product.^[11] An inorganic pyrophosphatase (PpA) can also be added to push the reaction towards completion in the direction of product formation.^[12] These enzymes can be used in one-pot (so called OPME) for efficient synthesis of glycans. Each OPME reaction is usually used to add one monosaccharide to a glycosyltransferase acceptor. Carrying out the OPME reactions sequentially allows the formation of complex carbohydrates and glycoconjugates. The stereo- and regiospecificities of the glycosidic bond formed, the nucleotide triphosphate required, and the selection of related sugar nucleotide biosynthetic enzymes are defined by the glycosyltransferases chosen based on the structures of the desired carbohydrate products. As OPME approaches are limited by the availability, expression level, solubility, stability for storage, and substrate specificity of the enzymes involved, identifying suitable glycosyltransferases and the corresponding sugar nucleotide biosynthetic enzymes is critical for developing efficient OPME systems.

To obtain lacto-*N*-neotetraose (LNnT), a common human milk tetrasaccharide (**3**), Lc₃ trisaccharide GlcNAcβ1–3Galβ1–4Glc (**2**) (Scheme 1) was synthesized from inexpensive disaccharide lactose (**1**) and monosaccharide *N*-acetylglucosamine (GlcNAc) using a one-pot four-enzyme GlcNAc activation and transfer system containing *Bifidobacterium longum* strain ATCC55813 *N*-acetylhexosamine-1-kinase (NahK),^[13] *Pasteurella multocida* *N*-acetylglucosamine uridyltransferase (PmGlmU),^[14] *Pasteurella multocida* inorganic pyrophosphatase (PmPpA),^[12] and *Neisseria meningitidis* β1–3-*N*-acetylglucosaminyltransferase (NmLgtA).^[15] In this system, adenosine 5'-triphosphate (ATP) and GlcNAc were used by NahK-catalyzed reaction to form GlcNAc-1-P, which was used with uridine 5'-triphosphate (UTP) by PmGlmU to form UDP-GlcNAc, the sugar nucleotide donor for NmLgtA for the production of Lc₃ from lactose. All four enzymes were quite active in Tris-HCl buffer at pH 8.0 and Lc₃ trisaccharide (1.36 g) was obtained in an excellent yield (95%) by incubation at 37 °C for 2 days.

Taking advantage of a promiscuous *Bifidobacterium longum* UDP-sugar pyrophosphorylase (BLUSP)^[16] which can produce uridine 5'-diphosphate galactose (UDP-Gal) directly from UTP and galactose-1-phosphate (Gal-1-P), LNnT Galβ1–4GlcNAcβ1–3Galβ1–4Glc (**3**) (1.19 g) was synthesized from Lc₃ (**2**) and a simple galactose (Gal) in an excellent yield (92%) using a one-pot four-enzyme galactosylation system^[17] containing *Escherichia coli* galactokinase (EcGalK),^[18] BLUSP,^[16] PmPpA,^[12] and *Neisseria meningitidis* β1–4-galactosyltransferase (NmLgtB).^[12] This is a more effective system compared to our previously reported OPME β1–4-galactosylation process which involved the formation of UDP-glucose (UDP-Glc) from glucose-1-phosphate (Glc-1-P) followed by C4-epimerization to produce UDP-Gal indirectly.^[12]

Initial sialylation of LNnT using *N*-acetylneuraminic acid (Neu5Ac) in a one-pot two-enzyme sialylation system^[19] containing *Neisseria meningitidis* CMP-sialic acid synthetase (NmCSS)^[19a] and *Photobacterium damsela* α2–6-sialyltransferase (Pd2,6ST)^[20] with an Neu5Ac to LNnT ratio of 1.5 to 1 produced an unexpected mixture of mono-sialylated and disialyl LNnT (DSLNNt) which were difficult to separate. Increasing the Neu5Ac to LNnT ratio to 2.4 to 1 led to the formation of DSLNNt hexasaccharide Neu5Acα2–6Galβ1–4GlcNAcβ1–3(Neu5Acα2–6)Galβ1–4Glc (**4**) (236 mg) in an excellent yield (99%). Nuclear magnetic resonance (NMR) data confirmed that Pd2,6ST does not only add a Neu5Ac α2–6-linked to the terminal Gal, it also adds an α2–6-linked Neu5Ac to the internal Gal residue in LNnT which is in consistent with the observation in a recent report.^[21] As shown in Table 1 using the beta-anomers (the major forms in D₂O solution) of the glycans for comparison, the attachment of Neu5Ac to the C-6 of the internal Gal (Gal^{II}) and the terminal Gal (Gal^{IV}) in LNnT results in significant downfield shifts of the substituted carbons (a downfield shift of 2.39 ppm for the C-6 of Gal^{II} and a downfield shift of 2.52 ppm for the C-6 of Gal^{IV}) in DSLNNt. There are obvious interactions of the Neu5Ac residues and GlcNAc^{III} and Glc^I which result in a significant downfield shift of 2.58 ppm for the C-4 of GlcNAc^{III} and a downfield shift of 1.55 ppm for the C-4 of Glc^I. These unusual chemical shift changes seen in Neu5Acα2–6Gal sialosides are in accordance with those observed for the glycans with same or similar structural element.^[22]

Disialyl LNT (DS'LNT) hexaose (Figure 2) Neu5Ac α 2–6Gal β 1–3GlcNAc β 1–3(Neu5Ac α 2–6)Gal β 1–4Glc (**5**) (268 mg) containing two sialic acid residues α 2–6-linked to the terminal and internal Gal residues of LNT, respectively, was also synthesized in an excellent yield (98%) using the same one-pot two-enzyme sialylation system containing NmCSS and Pd2,6ST with an Neu5Ac to LNT ratio of 2.6 to 1.

Two other disialyl glycans (Figure 2) including GD3 tetrasaccharide Neu5Ac α 2–8Neu5Ac α 2–3Gal β 1–4Glc (**6**) (239 mg), and disialyllactose (DSLac) Neu5Ac α 2–3(Neu5Ac α 2–6)Gal β 1–4Glc (**7**) (112 mg) were also synthesized, from Neu5Ac α 2–3Lac,^[23] using a one-pot two-enzyme sialylation system containing NmCSS and *Campylobacter jejuni* α 2–3/8-sialyltransferase (CjCstII; for GD3)^[24] or NmCSS and Pd2,6ST (for DSLac)^[20] (see SI for details).

As a control, a monosialyl pentasaccharide 3'''-sialyl LNnT (3'''-sLNnT) (**8**) (138 mg) (Figure 2) was synthesized from LNnT (**3**) using a one-pot two-enzyme sialylation system using NmCSS and a single-site mutant of *Pasteurella multocida* multifunctional α 2–3-sialyltransferase 1 (PmST1 M144D).^[25] Unlike Pd2, 6ST-catalyzed sialylation reaction which could add either one or two α 2–6-linked sialic acid residues to LNnT, PmST1 M144D-catalyzed sialylation reaction only added one α 2–3-linked sialic acid residue to the terminal Gal in LNnT. The use of PmST1 M144D mutant^[25] instead of the wild-type PmST1^[23] avoided the product hydrolysis by the α 2–3-sialidase activity of the wild-type enzyme, thus improved the yield of the one-pot two-enzyme α 2–3-sialylation reaction. Indeed, an excellent yield (98%) was achieved without the need of close monitoring and stopping the reaction process promptly.

The NEC-preventing effects of disialyl compounds DSLNnT (**4**), DS'LNT (**5**), GD3 (**6**), DSLac (**7**), and monosialyl compound 3'''-sLNnT (**8**) were tested in the same neonatal rat model that was used previously.^[3] A mixture of human milk oligosaccharides (HMOS) isolated from pooled human milk was used as a positive intervention control and a galactooligosaccharides (GOS) sample, shown to be ineffective in preventing NEC,^[3] was used as negative intervention control. As shown in Figure 3, dam-fed (DF) animals hardly developed any signs of NEC (mean pathology score 0.48 ± 0.41). Pathology scores were significantly higher in animals that were orally gavaged with rodent formula (FF) without the addition of glycans (2.06 ± 0.67 , $p < 0.0001$ compared to DF). Adding HMOS to the formula led to significantly lower pathology scores (0.85 ± 0.55 , $p < 0.0001$ compared to FF), which were not significantly different from the DF control ($p = 0.106$). Adding GOS had no effect on lowering pathology scores (2.00 ± 0.63 , $p = 0.790$ compared to FF). All these results are in accordance with the previously reported data.^[3] Adding the synthesized DSLNnT to the formula led to significantly lower pathology scores (1.32 ± 0.59 , $p < 0.001$ compared to FF), which was not significantly different from the effects seen in animals that received HMOS ($p = 0.062$), but still different from the DF control ($p < 0.001$). Adding the synthesized 3'''-sLNnT to the formula did not lower pathology scores ($2.05 \pm .55$, $p = 0.987$ compared to FF). Adding the synthesized DS'LNT to the formula significantly reduced pathology scores (1.21 ± 0.49 , $p < 0.001$ compared to FF), which again was not significantly different from the effects seen in animals receiving HMOS ($p = 0.120$), but still different from the DF control

($p < 0.001$). Neither GD3 nor DSLac had a significant effect on pathology scores compared to animals that received formula alone.

These results show that similar to DSLNT, DSLNnT and DS'LNT reduce pathology scores in an NEC neonatal rat model. All three compounds are disialyl hexasaccharides but with noticeable structural differences. Firstly, both DSLNT and DS'LNT are disialyl type I glycans whose core tetrasaccharide (LNT) has a Gal residue $\beta 1-3$ -linked to Lc₃ trisaccharide, while DSLNnT is a disialyl type II glycan whose core tetrasaccharide (LNnT) has a Gal residue $\beta 1-4$ -linked to the Lc₃ trisaccharide. Secondly, all three have a Neu5Ac $\alpha 2-6$ -linked to an internal monosaccharide, the internal monosaccharide is GlcNAc in DSLNT while a Gal in DSLNnT and DS'LNT. Thirdly, the outermost Neu5Ac is linked to the penultimate Gal in an $\alpha 2-3$ -linkage in DSLNT but an $\alpha 2-6$ -linkage in DSLNnT and DS'LNT. These structural differences of DSLNT, DSLNnT, and DS'LNT and their similarity in protecting neonatal rats from NEC indicate that the negatively charged disialyl component is important for the NEC preventing effect while the tetrasaccharide scaffold (type I or type II) does not seem to be important. The importance of disialyl component is further supported by the lacking of NEC preventing effect by monosialyl pentasaccharides such as LSTb^[3] shown previously and 3'''-sLNnT shown here. However, the presence of disialyl component alone is not sufficient to explain the beneficial effects as GD3 and DSLac showed no effect.

In conclusion, we have shown here that novel synthetic disialyl hexasaccharides, including disialyllacto-*N*-neotetraose (DSLNnT) and $\alpha 2-6$ -linked disialyllacto-*N*-tetraose (DS'LNT), can protect neonatal rats from NEC. Unlike the NEC-preventing DSLNT previously identified from human milk which is not easily obtainable by either purification or synthesis, the newly identified DSLNnT and DS'LNT are readily available by enzymatic synthesis. The sequential OPME systems described here allow the use of an inexpensive disaccharide and simple monosaccharides to synthesize desired complex oligosaccharide such as DSLNnT with high efficiency and selectivity. The readily available DSLNnT and DS'LNT are good therapeutic candidates for pre-clinical experiments and clinical application in treating NEC in preterm infants.

Experimental Section

Oligosaccharides **2-8** were prepared using one-pot multienzyme (OPME) reactions. Animal studies were reviewed and approved by the Institutional Animal Care Use Committee at the University of California, San Diego, AAALAC accreditation number 000503. Detailed synthetic procedures, NMR and high-resolution mass spectrometry (HRMS) characterization of the products including NMR spectra, and procedures for rat studies are available in the supporting information.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

References

1. Rudloff S, Kunz C. *Adv Nutr.* 2012; 3:398S–405S. [PubMed: 22585918]
2. a) Newburg DS, Ruiz-Palacios GM, Morrow AL. *Annu Rev Nutr.* 2005; 25:37–58. [PubMed: 16011458] b) Bode L. *Glycobiology.* 2012; 22:1147–1162. [PubMed: 22513036] c) Chichlowski M, German JB, Lebrilla CB, Mills DA. *Annu Rev Food Sci Technol.* 2011; 2:331–351. [PubMed: 22129386]
3. Jantscher-Krenn E, Zharebtsov M, Nissan C, Goth K, Guner YS, Naidu N, Choudhury B, Grishin AV, Ford HR, Bode L. *Gut.* 2012; 61:1417–1425. [PubMed: 22138535]
4. Kunz C, Rudloff S, Baier W, Klein N, Strobel S. *Annu Rev Nutr.* 2000; 20:699–722. [PubMed: 10940350]
5. Tao N, Ochonicky KL, German JB, Donovan SM, Lebrilla CB. *J Agri Food Chem.* 2010; 58:4653–4659.
6. a) Tao N, DePeters EJ, Freeman S, German JB, Grimm R, Lebrilla CB. *J Dairy Sci.* 2008; 91:3768–3778. [PubMed: 18832198] b) Aldredge DL, Geronimo MR, Hua S, Nwosu CC, Lebrilla CB, Barile D. *Glycobiology.* 2013; 23:664–676. [PubMed: 23436288]
7. Chaturvedi P, Warren CD, Altaye M, Morrow AL, Ruiz-Palacios G, Pickering LK, Newburg DS. *Glycobiology.* 2001; 11:365–372. [PubMed: 11425797]
8. de Heij HT, Koppen PL, van den Eijnden DH. *Carbohydr Res.* 1986; 149:85–99. [PubMed: 3731183]
9. a) Chen X, Varki A. *ACS Chem Biol.* 2010; 5:163–176. [PubMed: 20020717] b) Boons GJ, Demchenko AV. *Chem Rev.* 2000; 100:4539–4566. [PubMed: 11749357] c) Adak AK, Yu CC, Liang CF, Lin CC. *Curr Opin Chem Biol.* 2013; 17:1030–1038. [PubMed: 24182749]
10. Ando T, Ishida H, Kiso M. *Carbohydr Res.* 2003; 338:503–514. [PubMed: 12668106]
11. Chen X. *ACS Chem Biol.* 2011; 6:14–17. [PubMed: 21250649]
12. Lau K, Thon V, Yu H, Ding L, Chen Y, Muthana MM, Wong D, Huang R, Chen X. *Chem Commun.* 2010; 46:6066–6068.
13. Li Y, Yu H, Chen Y, Lau K, Cai L, Cao H, Tiwari VK, Qu J, Thon V, Wang PG, Chen X. *Molecules.* 2011; 16:6396–6407. [PubMed: 21799473]
14. Chen Y, Thon V, Li Y, Yu H, Ding L, Lau K, Qu J, Hie L, Chen X. *Chem Commun.* 2011; 47:10815–10817.
15. a) Guan W, Ban L, Cai L, Li L, Chen W, Liu X, Mrksich M, Wang PG. *Bioorg Med Chem Lett.* 2011; 21:5025–5028. [PubMed: 21704524] b) Blixt O, van Die I, Norberg T, van den Eijnden DH. *Glycobiology.* 1999; 9:1061–1071. [PubMed: 10521543]
16. Muthana MM, Qu J, Li Y, Zhang L, Yu H, Ding L, Malekan H, Chen X. *Chem Commun.* 2012; 48:2728–2730.
17. Malekan H, Fung G, Thon V, Khedri Z, Yu H, Qu J, Li Y, Ding L, Lam KS, Chen X. *Bioorg Med Chem.* 2013; 21:4778–4785. [PubMed: 23535562]
18. Chen X, Liu Z, Zhang J, Zhang W, Kowal P, Wang PG. *Chembiochem.* 2002; 3:47–53. [PubMed: 17590953]
19. a) Yu H, Yu H, Karpel R, Chen X. *Bioorg Med Chem.* 2004; 12:6427–6435. [PubMed: 15556760] b) Li Y, Yu H, Cao H, Lau K, Muthana S, Tiwari VK, Son B, Chen X. *Appl Microbiol Biotechnol.* 2008; 79:963–970. [PubMed: 18521592]
20. Yu H, Huang S, Chokhawala H, Sun M, Zheng H, Chen X. *Angew Chem Int Ed.* 2006; 45:3938–3944.
21. Nycholat CM, Peng W, McBride R, Antonopoulos A, de Vries RP, Polonskaya Z, Finn MG, Dell A, Haslam SM, Paulson JC. *J Am Chem Soc.* 2013; 135:18280–18283. [PubMed: 24256304]
22. a) Strecker G, Wieruszkeski JM, Michalski JC, Montreuil J. *Glycoconj J.* 1989; 6:67–83. [PubMed: 2535479] b) Sabesan S, Bock K, Paulson JC. *Carbohydr Res.* 1991; 218:27–54. [PubMed: 1802388]
23. Yu H, Chokhawala H, Karpel R, Yu H, Wu B, Zhang J, Zhang Y, Jia Q, Chen X. *J Am Chem Soc.* 2005; 127:17618–17619. [PubMed: 16351087]

24. a) Cheng J, Yu H, Lau K, Huang S, Chokhawala HA, Li Y, Tiwari VK, Chen X. *Glycobiology*. 2008; 18:686–697. [PubMed: 18509108] b) Yu H, Cheng J, Ding L, Khedri Z, Chen Y, Chin S, Lau K, Tiwari VK, Chen X. *J Am Chem Soc*. 2009; 131:18467–18477. [PubMed: 19947630]
25. Sugiarto G, Lau K, Qu J, Li Y, Lim S, Mu S, Ames JB, Fisher AJ, Chen X. *ACS Chem Biol*. 2012; 7:1232–1240. [PubMed: 22583967]

Figure 1.
The structure of disialyllacto-*N*-tetraose (DSLNT).

Figure 2.
Structures of DS'LNT hexaose, GD3 tetraose, and DSLac tetraose.

	DF	FF	HMOS	GOS	<u>DSL_{NnT}</u>	<u>3'''-sLN_{nT}</u>	<u>DS'LNT</u>	GD3
FF	<0.0001							
HMOS	<0.01	<0.0001						
GOS	<0.0001	<i>ns</i>	<0.0001					
<u>DSL_{NnT}</u>	<0.001	<0.001	<0.01	<0.01				
<u>3'''-sLN_{nT}</u>	<0.0001	<i>ns</i>	<0.0001	<i>ns</i>	<0.001			
<u>DS'LNT</u>	<0.001	<0.001	<i>ns</i>	<0.01	<i>ns</i>	<0.01		
GD3	<0.001	<i>ns</i>	<0.001	<i>ns</i>	<0.01	<i>ns</i>	<0.01	
<u>DSLac</u>	<0.001	<i>ns</i>	<0.001	<i>ns</i>	<0.01	<i>ns</i>	<0.01	<i>ns</i>

Figure 3.

DSL_{NnT} and DS'LNT protect neonatal rats from necrotizing enterocolitis. Ileum pathology scores (0: healthy; 4: complete destruction) are plotted for each animal in the different intervention groups. DF: dam fed (number of rats n=33); FF: fed formula without additional glycans (n=27); HMOS: FF contains oligosaccharides isolated from pooled human milk (2 mg/mL, n=23); GOS: FF contains galactooligosaccharides (2 mg/mL, n=15); DSL_{NnT}: FF contains DSL_{NnT} (300 µg/mL, n=20); 3'''-sLN_{nT}: FF contains 3'''-sLN_{nT} (300 µg/mL, n=19). DS'LNT: FF contains DS'LNT (300 µg/mL, n=14); GD3: FF contains GD3 (300 µg/mL, n=12); DSLac: FF contains DSLac (300 µg/mL, n=11). Bars represent mean ± standard deviation. p values are listed in the table below the figure. ns: not significant.

Scheme 1.

Sequential one-pot multienzyme (OPME) synthesis of lacto-*N*-neotetraose (LNnT) and DSLNnT. Enzymes: NahK, *N*-acetylhexosamine-1-kinase; PmGlmU, *Pasteurella multocida* *N*-acetylglucosamine uridyltransferase; PmPpA, a *Pasteurella multocida* inorganic pyrophosphatase; NmLgtA, β1-3-*N*-acetylglucosaminyltransferase; EcGalK, *Escherichia coli* galactokinase; BLUSP, *Bifidobacterium longum* UDP-sugar pyrophosphorylase; NmLgtB, *Neisseria meningitidis* β1-4-galactosyltransferase; NmCSS, *Neisseria meningitidis* CMP-sialic acid synthetase; Pd2,6ST, *Photobacterium damsela* α2-6-sialyltransferase.

Table 1

¹³C NMR chemical shifts for compounds Galβ1–4Glc (Lac), GlcNAcβ1–3Galβ1–4Glc (Lc₃ glycan), Galβ1–4GlcNAcβ1–3Galβ1–4Glc (LNnT), and Neu5Acα2–6Galβ1–4GlcNAcβ1–3(Neu5Acα2–6)Galβ1–4Glc (DSLNNnT). Significant chemical shift changes after sialylation for the formation of DSLNNnT from LNnT are highlighted in bold.

Sugar Unit	Carbon atoms	Lac	Lc ₃ glycan	LNnT	DSLNNnT
β-D-Glc ^I	1	95.64	95.66	95.61	95.70
	2	73.70	73.71	73.65	73.37
	3	74.26	74.20	74.22	74.36
	4	78.19	78.21	78.21	79.76
	5	74.69	74.71	74.76	74.76
	6	59.78	60.01	60.34	60.23
β-D-Gal ^{II} (1–4)	1	102.79	102.84	102.76	103.35
	2	70.86	70.03	69.88	69.76
	3	72.42	81.87	81.82	82.29
	4	68.46	68.26	68.22	68.32
	5	75.25	74.80	75.52	73.77
	6	60.94	60.88	60.84	63.23
β-D-GlcNAc ^{III} (1–3)	1		102.75	102.73	102.74
	2		56.58	56.52	54.83
	3		73.49	73.42	72.50
	4		69.92	78.11	80.69
	5		75.57	74.66	74.72
	6		60.41	59.93	60.05
	C=O		174.87	174.83	175.01
	CH ₃		22.09	22.03	22.38
β-D-Gal ^{IV} (1–4)	1			102.79	103.65
	2			70.99	70.83
	3			73.42	72.62

Sugar Unit	Carbon atoms	Lac	Lc ₃ glycan	LNn.T	DSL/Nn.T
α -D-Neu5Ac ^V (2-6)	4			68.24	68.47
	5			75.52	73.80
	6			60.85	63.37
	1				173.59
	2				100.38
	3				40.17
	4				68.47
	5				51.69
	6				72.64
α -D-Neu5Ac ^{VI} (2-6)	7				68.50
	8				71.86
	9				62.53
	C=O				175.01
	CH ₃				22.12
	1				173.66
	2				100.23
	3				40.17
	4				68.47
α -D-Neu5Ac ^{VI} (2-6)	5				51.79
	6				72.64
	7				68.50
	8				71.81
	9				62.53
	C=O				175.01
	CH ₃				22.15